← 홈

고형암 (전체) · VEGF

57개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 57개
AntibodyRochePhase 3

atezolizumab (Tecentriq, Atezolizumab + Bevacizumab)

Venous Thrombosis · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 49.3%임상시험 63상태 RECRUITING
AntibodyRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Bevacizumab)

Hepatocellular Carcinoma · Resectable Hepatocellular Carcinoma

#ResectableHepatocellularCarcinom#Antibody#Phase2#인기#항체+5
효능 ORR 50%임상시험 58상태 DISCONTINUED
AntibodyRochePreclinical

Bevacizumab + Erlotinib (Bevacizumab + Erlotinib)

Solid Tumor; Advanced Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Preclinical#인기#항체+4
효능 ORR 72%임상시험 52상태 RECRUITING
AntibodyNational Cancer Centre, Singapo…Phase 2

atezolizumab (Tecentriq, Adjuvant Atezolizumab-Bevacizumab Therapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 12상태 RECRUITING
AntibodyRochePreclinical

atezolizumab (Tecentriq, Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization)

Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Inter… · Advanced Hepatocellular Carcinoma (HCC),

#AdvancedHepatocellularCarcinomaH#Antibody#Preclinical#항체#면역항체+4
임상시험 3상태 RECRUITING
AntibodystaleRochePhase 2

bevacizumab (Avastin, Avastin (bevacizumab))

Recurrent Respiratory Papillomatosis · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 3상태 ACTIVE
AntibodyRochePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+carboplatin±bevacizumab)

Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent · Ovarian Carcinoma

#OvarianCarcinoma#Antibody#Phase2#항체#면역항체+4
임상시험 3상태 RECRUITING
AntibodystaleRochePreclinical

atezolizumab (Tecentriq, atezolizumab plus bevacizumab)

Hepatocellular Carcinoma; Hepatic Portal Vein Tumor Invasion · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#Antibody#Preclinical#항체#면역항체+4
효능 ORR 49.3%임상시험 3상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 ACTIVE
AntibodystaleRadboud University Medical Cent…Preclinical

111Indium-bevacizumab (111Indium-bevacizumab)

Clear Cell Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

#ClearCellRenalCellCarcinoma#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodyTae Won KimPhase 2

atezolizumab (Tecentriq, Aatezolizumab plus Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleLei LiPhase 2

Albumin-bound paclitaxel and bevacizumab (Albumin-bound paclitaxel and bevacizumab)

Ovarian Carcinoma; Platinum-resistant Ovarian Cancer · Ovarian Carcinoma

#OvarianCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodyRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab combined with β- alanine)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Belinostat, carboplatin, paclitaxel and bevacizumab (Belinostat, carboplatin, paclitaxel and bevacizumab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

adjuvant (Bevacizumab, Bevacizumab (adjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 41.7%임상시험 1상태 RECRUITING
AntibodystaleRochePhase 1

and approved biosimilars (Bevacizumab, Bevacizumab (and approved biosimilars))

Solid Tumor; Colorectal Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

Bevacizumab Biosimilar IBI305 (Bevacizumab Biosimilar IBI305)

Post-orthotopic Liver Transplantation; Hepatocellular Carcinoma Recurrent · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

Bevacizumab Biosimilar IBI305 plus sintilimab (Bevacizumab Biosimilar IBI305 plus sintilimab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 1

Bevacizumab and Sunitinib (Bevacizumab and Sunitinib)

Metastatic Renal Cell Carcinoma; Kidney Cancer · Metastatic Renal Cell Carcinoma

#MetastaticRenalCellCarcinoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab combined with Sintilimab (Bevacizumab combined with Sintilimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING

1 / 3 페이지

← 이전다음 →